Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Southwest Oncology Group National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00066794 |
RATIONALE: Drugs used in chemotherapy, such as cyclosporine, daunorubicin, and cytarabine, use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
PURPOSE: This phase II trial is studying how well giving cyclosporine together with daunorubicin and cytarabine works in treating older patients with untreated acute myeloid leukemia.
Condition | Intervention | Phase |
---|---|---|
Leukemia |
Drug: cyclosporine Drug: cytarabine Drug: daunorubicin hydrochloride Drug: filgrastim Drug: sargramostim |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | A Phase II Study Of Induction With Daunorubicin, Cytarabine, And Cyclosporine All By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older |
Estimated Enrollment: | 64 |
Study Start Date: | July 2004 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
Patients are followed every 3 months for 1 year, every 6 months for 1 year, and then annually for 3 years.
PROJECTED ACCRUAL: A total of 25-64 patients will be accrued for this study within 13 months.
Ages Eligible for Study: | 56 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Morphologically confirmed acute myeloid leukemia (AML)
Differential diagnosis of AML based on FAB classification system
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Cardiovascular
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Investigator: | Thomas R. Chauncey, MD, PhD | Veterans Affairs Medical Center - Seattle |
Investigator: | Cheryl L. Willman, MD | University of New Mexico |
Investigator: | Marilyn L. Slovak, PhD | Beckman Research Institute |
Study ID Numbers: | CDR0000318831, SWOG-S0301 |
Study First Received: | August 6, 2003 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00066794 |
Health Authority: | United States: Federal Government |
adult acute monocytic leukemia (M5b) adult acute megakaryoblastic leukemia (M7) adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia with maturation (M2) adult acute myeloblastic leukemia without maturation (M1) adult acute myelomonocytic leukemia (M4) adult acute monoblastic leukemia (M5a) |
untreated adult acute myeloid leukemia adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult pure erythroid leukemia (M6b) adult erythroleukemia (M6a) |
Leukemia, Monocytic, Acute Daunorubicin Cyclosporine Clotrimazole Miconazole Tioconazole Acute myelogenous leukemia Acute myelomonocytic leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Di Guglielmo's syndrome |
Cyclosporins Leukemia, Myelomonocytic, Acute Leukemia Leukemia, Erythroblastic, Acute Acute erythroblastic leukemia Acute myeloid leukemia, adult Congenital Abnormalities Acute myelocytic leukemia Acute monoblastic leukemia Cytarabine |
Antimetabolites Anti-Infective Agents Antimetabolites, Antineoplastic Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Physiological Effects of Drugs Enzyme Inhibitors |
Antibiotics, Antineoplastic Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Neoplasms Antifungal Agents Therapeutic Uses Antirheumatic Agents Dermatologic Agents |